Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
13 hedge funds and large institutions have $1.69M invested in Sonnet BioTherapeutics in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
44% more funds holding
Funds holding: 9 → 13 (+4)
1% more capital invested
Capital invested by funds: $1.67M → $1.69M (+$22K)
0% less ownership
Funds ownership: 0% → 0% (-0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$970K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$436K |
| 3 |
Renaissance Technologies
New York
|
+$105K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$33.4K |
| 5 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
+$15.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$2.23K |
| 2 |
Citigroup
New York
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $1.08M | +$970K | +436 | +153% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $301K | +$436K | +196 | +3,267% |
|
3
BlackRock
New York
| $111K | – | – | – |
|
|
4
Renaissance Technologies
New York
| $70K | +$105K | +47 | New |
|
5
State Street
Boston,
Massachusetts
| $38K | – | – | – |
|
6
T. Rowe Price Associates
Baltimore,
Maryland
| $27K | – | – | – |
|
|
TSS
7
Two Sigma Securities
New York
| $22K | +$33.4K | +15 | New |
|
|
ASN
8
Advisory Services Network
Atlanta,
Georgia
| $20K | -$2.23K | -1 | -7% |
|
|
BPA
9
Beacon Pointe Advisors
Newport Beach,
California
| $11K | +$15.6K | +7 | New |
|
10
UBS Group
Zurich,
Switzerland
| $7K | +$8.9K | +4 | New |
|
|
MSFS
11
Main Street Financial Solutions
Newtown,
Pennsylvania
| $6K | – | – | – |
|
|
IA
12
IFP Advisors
Tampa,
Florida
| $1K | – | – | – |
|
13
Morgan Stanley
New York
| $1K | – | – | – |
|
|
14
Citigroup
New York
| – | -$2K | – | – |
|
SONN Hedge Fund Activity: Q3 2021 in Review
13 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q3 2021, worth a combined $1.69M — up 1.3% from $1.67M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new SONN positions and 0 closed out — a net gain of 4 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, adding an estimated $970K. The largest seller was Advisory Services Network, cutting an estimated $2.23K.
- 13 institutional investors held Sonnet BioTherapeutics (SONN) as of Q3 2021, up from 9 in Q2 2021.
- Funds reported $1.69M of Sonnet BioTherapeutics stock for Q3 2021, up 1.3% quarter-over-quarter.
- 4 funds opened new Sonnet BioTherapeutics positions in Q3 2021 and 0 closed out, a net change of +4 holders.
- The largest Sonnet BioTherapeutics buyer in Q3 2021 was Vanguard Group, an estimated $970K added.
- The largest Sonnet BioTherapeutics seller in Q3 2021 was Advisory Services Network, an estimated $2.23K sold.
Based on aggregated 13F filings for Q3 2021.